Skip to main content
OpenTrials

Clinical trial condition

Alagille Syndrome

Explore clinical trials studying Alagille Syndrome. Study availability and eligibility vary by location and protocol.

21 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Alagille Syndrome trial results

Recruiting

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

NCT07585097

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +11 more
Locations
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant Bron, France
  • CHU Dijon Bourgogne Dijon, France
  • APHP - Hopital Bicetre - Paris Sud Le Kremlin-Bicêtre, France
  • APHM - CHU Timone Marseille, France
View all 14 locations
View Trial Details
Recruiting

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

NCT06850038

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +11 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • UCSF Benioff Children's Hospital San Francisco, California, United States
  • The Children's Mercy Hospital Kansas City, Missouri, United States
  • SSM Health Cardinal Glennon Children's Hospital St Louis, Missouri, United States
View Trial Details
Recruiting

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

NCT07290257

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +19 more
Locations
  • Cliniques Universitaires Saint Luc (UCLouvain) Brussels, Belgium
  • University Hospital Gent (UZ Gent) Ghent, Belgium
  • Hospices Civils de Lyon - Hopital Femme Mère Enfant Bron, Auvergne-Rhône-Alpes, France
  • CHU de Toulouse - Hôpital des Enfants Toulouse, Occitanie, France
View all 15 locations
View Trial Details
Recruiting

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

NCT06193928

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +13 more
Locations
  • Children's Hospital Los Angeles CHLA Los Angeles, California, United States
  • Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado Aurora, Colorado, United States
  • Children's Healthcare of Atlanta - Emory University School of Medicine Atlanta, Georgia, United States
  • Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology Kansas City, Missouri, United States
View Trial Details
Active, not recruiting

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

NCT05035030

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +11 more
Locations
  • Rady Children's Hospital San Diego, California, United States
  • UCSF San Francisco, California, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • Riley Hospital for Children at IU Health Indianapolis, Indiana, United States
View all 35 locations
View Trial Details
Completed

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

NCT04729751

Conditions
Abnormalities, Multiple, Alagille Syndrome, Bile Duct Diseases, +14 more
Locations
  • Children Hospital LA Los Angeles, California, United States
  • University of California - San Francisco San Francisco, California, United States
  • Medstar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Ochsner Hospital for Children New Orleans, Louisiana, United States
View all 14 locations
View Trial Details
Completed

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

NCT02922751

Conditions
Abnormalities, Multiple, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, +26 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • University of California at San Francisco (UCSF) San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's Healthcare of Atlanta (Emory University) Atlanta, Georgia, United States
View all 13 locations
View Trial Details

Related conditions